These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20687217)

  • 1. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
    Musende AG; Eberding A; Jia W; Ramsay E; Bally MB; Guns ET
    Prostate; 2010 Sep; 70(13):1437-47. PubMed ID: 20687217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.
    Musende AG; Eberding A; Wood CA; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Tomlinson Guns ES
    Anticancer Drugs; 2012 Jun; 23(5):543-52. PubMed ID: 22481061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
    Musende AG; Eberding A; Wood C; Adomat H; Fazli L; Hurtado-Coll A; Jia W; Bally MB; Guns ET
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1085-95. PubMed ID: 19301006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
    Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
    J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
    Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
    Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective.
    Ben-Eltriki M; Shankar G; Tomlinson Guns ES; Deb S
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):419-437. PubMed ID: 37709921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitriol and 20(S)-protopanaxadiol synergistically inhibit growth and induce apoptosis in human prostate cancer cells.
    Ben-Eltriki M; Deb S; Adomat H; Tomlinson Guns ES
    J Steroid Biochem Mol Biol; 2016 Apr; 158():207-219. PubMed ID: 26709138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
    Hwang JJ; Kim YS; Kim MJ; Kim DE; Jeong IG; Kim CS
    J Urol; 2010 Dec; 184(6):2557-64. PubMed ID: 21030039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
    Freitas M; Alves V; Sarmento-Ribeiro AB; Mota-Pinto A
    Biochem Biophys Res Commun; 2011 May; 408(4):713-9. PubMed ID: 21549092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
    Pinto AC; Moreira JN; Simões S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):445-54. PubMed ID: 19104815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1α,25-Dihydroxyvitamin D
    Ben-Eltriki M; Deb S; Guns EST
    J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis.
    Reiner T; de las Pozas A; Gomez LA; Perez-Stable C
    Cancer Lett; 2009 Apr; 276(1):21-31. PubMed ID: 19046802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
    Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kälkner KM; Lennernäs B; Nilsson S
    Acta Oncol; 2005; 44(6):644-50. PubMed ID: 16165924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.
    Lin E; Wang Q; Swenson S; Jadvar H; Groshen S; Ye W; Markland FS; Pinski J
    Prostate; 2010 Sep; 70(12):1359-70. PubMed ID: 20623636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells.
    Liu J; Shimizu K; Yu H; Zhang C; Jin F; Kondo R
    Fitoterapia; 2010 Oct; 81(7):902-5. PubMed ID: 20554003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
    Fischel JL; Ciccolini J; Formento P; Ferrero JM; Milano G
    Anticancer Drugs; 2006 Aug; 17(7):807-13. PubMed ID: 16926630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.